for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

CYAD.OQ

Latest Trade

10.00USD

Change

-0.16(-1.57%)

Volume

5,230

Today's Range

9.94

 - 

10.15

52 Week Range

9.04

 - 

28.89

As of on the NASDAQ Stock Exchange Global Market ∙ Minimum 15 minute delay

Pricing

Previous Close
10.16
Open
10.15
Volume
5,230
3M AVG Volume
1.33
Today's High
10.15
Today's Low
9.94
52 Week High
28.89
52 Week Low
9.04
Shares Out (MIL)
13.94
Market Cap (MIL)
129.38
Forward P/E
-3.86
Dividend (Yield %)
--

Latest Developments

More

Celyad: Closing Of 20 Million Dollars Global Offering

Celyad Announces Pricing of $20.0 Million Global Offering

Celyad SA - Intends To Offer & Sell Up To 2 Million Ordinary Shares In A Global Offering

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About

Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company's product, C-Cure, allows the differentiation of a patient's own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle. C-Cure consists of autologous adult stem cells guided in vitro to the cardiac lineage before implantation in the failing heart. Furthermore, the Company is involved in the field of immuno-oncology, through its subsidiary, OnCyte.

Industry

Healthcare Facilities

Contact Info

Rue Edouard Belin 12

+32.10.394100

https://www.celyad.com/

Executive Leadership

Michel E J Lussier

Chairman of the Board, Co-Founder

Filippo J. Petti

Chief Executive Officer, Chief Financial Officer

Gaetane Metz

Chief Operating Officer

Carri Duncan

Vice President Corporate Development and Communications

Anne Moore

Vice President Corporate Strategy

Key Stats

1.67 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (EUR)

2016

-2.530

2017

-5.860

2018

-3.360

2019(E)

-2.165
Price To Earnings (TTM)
--
Price To Sales (TTM)
216.73
Price To Book (MRQ)
2.71
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
12.06
LT Debt To Equity (MRQ)
8.53
Return on Investment (TTM)
-40.77
Return on Equity (TTM)
-36.69

Latest News

BRIEF-Celyad Says Grade 4 Adverse Events Occurred In Two THINK Trial Patients, Announces Q1 Business Update

* GRADE 4 SERIOUS ADVERSE EVENTS OCCURRED IN TWO PATIENTS OF CYAD-01 THINK TRIAL OUT OF 20 PATIENTS INCLUDED IN INTERIM SAFETY REPORT

BRIEF-Celyad Successfully Administers CYAD-01 In First Patients In Shrink And Link Trials

* CELYAD SUCCESSFULLY ADMINISTERS CYAD-01 IN FIRST PATIENTS IN SHRINK AND LINK TRIALS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Celyad's CYAD-01 Induced Complete Remission In Relapsed/Refractory AML Patient

* HAEMATOLOGICA PUBLISHES CELYAD THINK STUDY CASE REPORT OF CYAD-01 INDUCED COMPLETE REMISSION IN RELAPSED/REFRACTORY AML PATIENT

BRIEF-Celyad To Present Updates On CYAD-01 At American Association For Cancer Research Annual Meeting

* CELYAD TO PRESENT UPDATES ON CYAD-01 AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING 2018

BRIEF-Celyad ends Q3 with EUR 40 million in cash, confirms previous guidance

* CONFIRMS ITS PREVIOUS GUIDANCE THROUGH TO THE FIRST HALF 2019 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Celyad reports first complete response in relapsed refractory AML patient in THINK trial

* REPORTS A FIRST COMPLETE RESPONSE IN A RELAPSED REFRACTORY AML PATIENT IN THE THINK TRIAL

BRIEF-Celyad SA files for mixed shelf offering of up to $250 mln

* Celyad SA files for mixed shelf offering of up to $250 million - SEC filing Source text: [http://bit.ly/2xBg9Sn] Further company coverage:

BRIEF-Celyad H1 operating loss narrows to 13.7 million euros

* H1 OPERATING LOSS EUR 13.7 MILLION VERSUS LOSS OF EUR 17.2 MILLION YEAR AGO

BRIEF-BioLife Solutions executes supply agreement with Celyad for CryoStor

* Biolife Solutions executes supply agreement with Celyad for CryoStor use in natural killer receptor based t-cell (nkr-t) platform targeting solid tumors and blood cancers

BRIEF-Celyad announces initiation of the SHRINK trial

* SHRINK TRIAL IS THIRD CLINICAL TRIAL WITH ITS LEAD PRODUCT CANDIDATE CYAD-01 (CAR-T NKG2D), TARGETING METASTATIC COLORECTAL PATIENTS

BRIEF-Celyad publishes additional pre-clinical data in support of THINK trial

* PUBLISHES ADDITIONAL PRE-CLINICAL DATA IN SUPPORT OF THINK TRIAL

BRIEF-Celyad obtains additional US patent for allogeneic cancer treatment based on TCR-deficient CAR-T cells

* CELYAD OBTAINS ADDITIONAL US PATENT FOR ALLOGENEIC CANCER TREATMENT BASED ON TCR-DEFICIENT CAR-T CELLS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Celyad ends Q1 with EUR 72.4 mln in cash

* USE OF CASH OVER Q1 OF 2017 AMOUNTED TO EUR 10.2 MILLION, IN LINE WITH EXPECTATIONS

BRIEF-FDA grants fast track designation for Celyad's ischemic heart failure therapy, C-Cure

* FDA GRANTS FAST TRACK DESIGNATION FOR CELYAD’S ISCHEMIC HEART FAILURE THERAPY, C-CURE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-Deficient CAR-T Cells Patents

* Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-Deficient CAR-T Cells Patents

BRIEF-Celyad FY EBIT loss narrows at 25.6 million euros

* FY loss of 23.6 million euros versus loss of 29.1 million euros year ago

BRIEF-Celyad: USPTO rejects new reexamination request against Celyad's US patent for production of allogeneic TCR-deficient CAR-T cells

* The U.S. Patent and Trademark Office (USPTO) rejects new reexamination request against Celyad's US patent for production of allogeneic TCR-deficient CAR-T cells

BRIEF-Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in US

* Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Celyad registers first hematological patient in CAR-T NKR-2 THINK trial

* Celyad registers first hematological patient in CAR-T NKR-2 THINK trial

BRIEF-Celyad announces registration of first pancreatic cancer patient in its CAR-T NKR-2 THINK Trial in Belgium

* Announces registration of first pancreatic cancer patient in its CAR-T NKR-2 THINK Trial in Belgium Source text: http://bit.ly/2jjM82G Further company coverage: (Gdynia Newsroom)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up